Paul Hachem
Overview
Explore the profile of Paul Hachem including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
126
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Udayakumar T, Stoyanova R, Hachem P, Ahmed M, Pollack A
Int J Radiat Oncol Biol Phys
. 2011 Jan;
79(2):549-58.
PMID: 21195876
Purpose: We previously showed that E2F1 overexpression radiosensitizes prostate cancer cells in vitro. Here, we demonstrate the radiosensitization efficacy of adenovirus (Ad)-E2F1 infection in growing (orthotopic) LNCaP and (subcutaneous) PC3...
2.
Chen L, Mu Z, Hachem P, Ma C, Wallentine A, Pollack A
Phys Med Biol
. 2010 Nov;
55(24):7399-410.
PMID: 21098923
The purpose of this study is to quantify the enhancement of [³H]-docetaxel in implanted prostate tumors treated with MR-guided pulsed focused ultrasound (MRgFUS). Human prostate cancer, LNCaP cells in 25...
3.
Hensley H, Hannoun-Levi J, Hachem P, Mu Z, Stoyanova R, Khor L, et al.
Int J Cancer
. 2010 Oct;
128(4):962-73.
PMID: 20960462
The therapeutic efficacy of Gem®231, a second generation antisense molecule targeted to the RIα subunit of PKA(RIα) (AS-PKA), administered in combination with androgen deprivation (AD) and radiation therapy (RT), was...
4.
Udayakumar T, Hachem P, Ahmed M, Agrawal S, Pollack A
Mol Cancer Res
. 2008 Nov;
6(11):1742-54.
PMID: 19010821
We have previously shown in separate studies that MDM2 knockdown via antisense MDM2 (AS-MDM2) and E2F1 overexpression via adenoviral-mediated E2F1 (Ad-E2F1) sensitized prostate cancer cells to radiation. Because E2F1 and...
5.
Mu Z, Hachem P, Hensley H, Stoyanova R, Kwon H, Hanlon A, et al.
Prostate
. 2008 Jan;
68(6):599-609.
PMID: 18196567
Background: Antisense MDM2 oligonucleotide (AS-MDM2) sensitizes androgen sensitive LNCaP cells to androgen deprivation (AD) in vitro and in vivo. In this study, we investigated the effects of AS-MDM2 combined with...
6.
Stoyanova R, Hachem P, Hensley H, Khor L, Mu Z, Hammond M, et al.
Int J Radiat Oncol Biol Phys
. 2007 Jul;
68(4):1151-60.
PMID: 17637390
Purpose: To test the effects of antisense (AS)-MDM2 alone and with androgen deprivation (AD), radiotherapy (RT), and AD + RT on wild-type LNCaP cells in an orthotopic in vivo model....
7.
Mu Z, Hachem P, Pollack A
Prostate
. 2005 Jul;
65(4):331-40.
PMID: 16015611
Background: Bcl-2 is anti-apoptotic and overexpression is associated with prostate tumor aggressiveness. We hypothesized that Bcl-2 has a role in prostate cancer radiation (RT) response. The relationship of Bcl-2 expression...
8.
Nguyen K, Hachem P, Khor L, Salem N, Hunt K, Calkins P, et al.
Int J Radiat Oncol Biol Phys
. 2005 Jul;
63(1):238-46.
PMID: 15993550
Purpose: E2F-1 is a transcription factor that enhances the radiosensitivity of various cell lines by inducing apoptosis. However, there are conflicting data concerning whether this enhancement is mediated via p53...
9.
Mu Z, Hachem P, Agrawal S, Pollack A
Prostate
. 2004 Jun;
60(3):187-96.
PMID: 15176048
Background: Early in the malignant transformation of prostate epithelial cells, the apoptotic response to androgen deprivation (AD) is lost and the principle response is a slowing of cell growth. In...
10.
Mu Z, Hachem P, Agrawal S, Pollack A
Int J Radiat Oncol Biol Phys
. 2004 Jan;
58(2):336-43.
PMID: 14751501
Purpose: Antisense MDM2 (AS) sensitizes a variety of tumor cell types, including prostate cancer, to radiation and chemotherapy. We have previously described that AS enhances the apoptotic response to androgen...